CTRI/2020/05/024972已完成3 期
A randomized, double blind, parallel group, reference controlled study to evaluate the safety and efficacy of Consolax TM powder in patients with Irritable Bowel Syndrome having constipation
Zeushygia Life Sciences Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Male or female subjects ranging in age from 18 to 65 years (both inclusive) diagnosed as having gastro intestinal disorders by the Investigator.
- •2.Fulfilling Rome IV Diagnostic Criteria for Functional IBS. Criterion fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis
- •a)Recurrent abdominal pain on average at least 1 day/week in the last 3 months, associated with two or more of the following criteria:
- •i.Related to defecation
- •ii.Onset associated with a change in frequency of stool
- •iii.Onset associated with a change in form (appearance) of stool
- •b)Recurrent feeling of bloating or visible distension at least 1 day/week in the last 3 months
- •c)Disordered bowel habits are typically present (constipation, diarrhoea or a mix of constipation and diarrhoea)
- •3.Willingness to follow the protocol requirement as evidenced by written, informed consent.
- •4.Willingness to complete subject diaries and study questionnaires.
- •5.Agree not to use any medication (prescription and over the counter), including vitamins and minerals, during the course of this study.
- •6.Agree not to use any yogurt and be on stable fiber therapy during the course of this study.
- •7.Subjects whose blood chemistries are within a normal range or not considered clinically significant if outside the normal range
- •8.Subjectâ??s assurance that they have not taken antibiotics or other drugs whose primary site of action is in the GIT for a period up to 1 month prior to the start of the study.
- •9.Normal colonoscopy/sigmoidoscopy
- •10.Able to refrain from use of medications known to treat or associated with constipation symptoms
排除标准
- •1.Sufficient criteria for a diagnosis of functional dyspepsia or other functional GI disorders
- •2.Diarrhoea-predominant or alternating (diarrhoea and constipation cycling) irritable bowel syndrome (IBS), or constipation other than that associated with IBS
- •3.Any clinically significant medical history, medical finding or an ongoing medical or psychiatric and /or prior abdominal or GI surgical condition exists which in the opinion of the Investigator could jeopardize the safety of the subject, impact validity of the study results or interfere with the completion of study according to the protocol
- •4.Organic bowel disorder, mechanical bowel obstruction, pseudo-obstruction, unexplained weight loss or rectal bleeding.
- •5.Significant abnormal findings as determined by baseline history, physical examination, vital signs (blood pressure, pulse rate, respiration rate) hematology, serum chemistry, urinalysis.
- •6.History or presence of significant alcoholism or drug abuse in the past one year.
- •7.Participation in a clinical study during the preceding 90 days.
- •8.History of malignancy or other serious disease.
- •9.Any contraindication to blood sampling.
- •10.Smoking or Consumption of tobacco products.
- •11.Blood or blood products donated in past 30 days prior to study supplement administration.
- •12.Female subjects on pregnancy and lactating women.
研究者
相似试验
招募中
3 期
Comparing the safety and efficacy of Altelyse with Actilyse in acute myocardial infarctioIRCT20190729044366N1Arena Life Science Company150
进行中（未招募）
不适用
A randomized, double-blind, parallell-group, controlled study of topical pentane-1,5-diol hydrogel in patients with impetigoImpetigoEUCTR2005-000808-14-SEAmbria Dermatology88
进行中（未招募）
1 期
A randomised, double-blind, parallel group, multiple-dose 3 month study of ibuprofen 400mg alone, paracetamol (acetaminophen) 1000mg alone, ibuprofen 200mg plus paracetamol 500mg and ibuprofen 400mg plus paracetamol 1000mg, all taken three times daily, in community patients with chronic knee pain. - Ibuprofen plus paracetamol (acetaminophen) in knee pain.Pain.MedDRA version: 8.1 Level: LLT Classification code 10033371 Term: PainEUCTR2006-005668-21-GBReckitt Benckiser Healthcare International Limited892
已完成
不适用
Ibuprofen plus paracetamol in knee paiISRCTN77199439RB Corporate Services Ltd (UK)800
招募中
2 期
Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin Compared to Each Monotherapy, in Adult Patients With NASH and Liver FibrosisCTRI/2020/08/027184ovartis Healthcare Pvt Ltd